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Abstract
The application of nanotechnology in biological research is beginning to have a major impact leading to the development of
new types of tools for human health. One focus of nanobiotechnology is the development of nanoparticle-based formulations
for use in drug or gene delivery systems. However most of the nano probes currently in use have varying levels of toxicity in
cells or whole organisms and therefore are not suitable for in vivo application or long-term use. Here we test the potential of a
novel silica based nanoparticle (organically modified silica, ORMOSIL) in livingneurons within a whole organism. We show that
feeding ORMOSIL nanoparticles to Drosophila has no effect on viability. ORMOSIL nanoparticles penetrate into living brains,
neuronal cell bodies and axonal projections. In the neuronal cell body, nanoparticles are present in the cytoplasm, but not in
the nucleus. Strikingly, incorporation of ORMOSIL nanoparticles into the brain did not induce aberrant neuronal death or
interfered with normal neuronal processes. Our results in Drosophila indicate that these novel silica based nanoparticles are
biocompatible and not toxic to whole organisms, and has potential for the development of long-term applications.
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Introduction
The use of nanotechnology in biomedical research is expected
to have a major impact on human welfare, due to the development
of new types of diagnostic and therapeutic tools. However, the
same properties that make nanoparticles so attractive for
development in nanomedicine could also prove deleterious when
nanoparticles interact with cells within a living organism. Indeed,
there are a number of nano probes (quantum dots (QDs) [1],
upconverting nanophosphors [2], and luminophore-containing
nanoparticulate carriers such as liposomes [3], polymersomes [4]
ceramic [5,6], or polymeric [7] nanoparticles), which claim to be
efficient theranostic tools for in vivo imaging and also have potential
for use in therapeutic applications. However, many of these nano
probes have long-term toxicity issues that dilute their efficiency for
long-term use in vivo.
Recently, interest has generated in the use of new silica-based
nanoparticles for imaging. Silica-based nanomaterials such as sol-
gel, colloidal, mesoporous and organically modified silica (OR-
MOSIL) nanoparticles, have shown promising potential in
biotechnological applications such as nanoprobes for actively
targeted optical imaging [8,9]. These inert, optically transparent
materials can be conjugated with any desired fluorophore (visible
or NIR), leading to the generation of robust, fluorescent
nanoparticles [10,11]. Furthermore, these nanoparticles are
porous and have tunable pore size, so they can be incorporated
with bioactive molecules such as enzymes, genetic materials, and
chemotherapeutic drugs. They can also be tagged with a peptide
for a specific biological function [12,13], thus allowing targeting to
specific cell types or tissues. In addition, the chemistry of silica
provides the opportunity for a variety of surface functionalities
(hydroxyl/amino/thiol/carboxyl groups, [14,15]), which can be
used to attach biotargeting molecules. Previously ORMOSIL
nanoparticles conjugated with fluorophores and targeting ligands
have been used in optical imaging of tumor cells in vitro [16,17].
These particles have also been tested for potential use in
photodynamic therapy, and as targeted optical probes for imaging
of pancreatic cancer cells in in vitro experiments [18,19,20].
However, to date the biocompatibility, bio distribution and
toxicity of ORMOSIL has not been tested in living organisms.
Drosophila melanogaster is an ideal model system to rapidly test
novel nanoparticles that have potential therapeutic applicability
for human diseases. The Drosophila genome is highly conserved
when compared to higher organisms. Many homologous genes
encoding proteins that cause human diseases have been identified
[21]. Many human neuronal disease models such as Alzheimer’s
disease, Huntington’s disease and Parkinson’s disease have also
been developed in the fly [22]. Furthermore, cellular and
developmental mechanisms are extensively conserved between
flies and humans. Thus studies on the uptake of new therapeutic
agents and their lethality in Drosophila can be well correlated to
mammalian systems. The developmental and behavioral aspects of
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informative and adaptable model to investigate a wide variety of
toxicological endpoints relevant to human biology. Recently, a
number of powerful assay methods have been developed in
Drosophila to test developmental and behavioral toxicology of
potential therapeutic agents. Results from these tests have been
used to prioritize further testing in rodents, and some of these
agents have later been translated into human clinical trails
[23,24,25].
Here we report the in vivo characterization of a novel silica based
nanoparticle, ORMOSIL in Drosophila. We provide evidence
that these nanoparticles are biocompatible and can be effectively
used in living organisms for a long period of time. We show that
these nanoparticles are not toxic to the developing organism
and do not disrupt any major cellular functions. ORMOSIL
nanoparticles readily incorporate into living neuronal cells.
Incorporation of ORMOSIL does not activate aberrant neuronal
death pathways, nor does it affect the long distance transport
pathway (axonal transport), which is essential for the growth,
maintenance and survival of all neurons. Taken together, our
results suggest that ORMOSIL nanoparticles can be safely used in
living neuronal tissues and in living organisms with minimal effects
on normal cellular functions. This is the first study that thoroughly
investigates the biocompatibility of this class of nanoparticles
throughout an organism’s development and in neuronal cells,
which is an important consideration for these particles to be
eventually translated into use in humans.
Results
Physiochemical properties of ORMOSIL nanoparticles
To test the biocompatibility, bio distribution, and the eventual
fate of ORMOSIL nanoparticles in vivo following systemic
delivery, we used fluorescently conjugated ORMOSIL. We use
both unconjugated and conjugated (receptor and peptide-conju-
gated) rhodamine-ORMOSIL nanoparticles (
RORM). The syn-
thesis of the
RORM nanoparticles was adapted from our previous
work with minor modifications [8, 26] and the nanoparticles were
characterized by various methods as described in figure 1. Figure 1,
shows the basic properties of
RORM including its absorption and
emission spectra.
RORM emits at a typical emission band for
rhodamine, which is lmax 600 nm (Figure 1A). The size distri-
bution profile as measured by dynamic light scattering (DLS)
method (Figure 1B) and transmission electron microscopy (TEM,
Figure 1C) indicate that the diameter of
RORM particles are on
average 20 nm, much smaller than the average diameter of
synaptic vesicles, which are on average about 40 nm [27]. For
receptor-conjugated
RORM, we use the transferrin receptor (TfR,
TfR-
RORM). Transferrin bound TfR receptor is transported into
the cell by endocytosis in a vesicle [28] and is the major route of
cellular iron uptake. This cellular uptake pathway is currently
being exploited for site-specific delivery of anticancer drugs and
therapeutic genes into proliferating malignant cells [29]. For
peptide-conjugated
RORM (peptide-
RORM), we used 15aa of the
C-terminus of the amyloid precursor protein (APP). APP
transports a subclass of vesicles in the anterograde direction down
the axon [30]. Both conjugation strategies involved the use of
simple Ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDCI)
chemistry using the functional amine groups present on the
surface of
RORM and carboxyl group of APP. Recent work has
shown that 15aa of the C-terminus of APP is sufficient for APP to
bind to the anterograde molecular motor for axonal transport
[31]. Both TfR-
RORM and peptide-
RORM particles have similar
diameters as unconjugated
RORM, and these particles resemble
the size of biological vesicles. As a control for fluorescence and to
see the applicability of ORMOSIL nanoparticles with different
fluorophores, we tested cy5 conjugated ORMOSIL (
cy5ORM,
Figure S1, Table 1) and observe similar effects as
RORM (see
below). In addition, although in many of our experiments (Table 1)
we have used
cy5ORM we have focused on
RORM as the main
formulation.
Drosophila development is not affected by ORMOSIL
particles
To test the biocompatibility of ORMOSIL in a living organism,
we used Drosophila as a model system. Because of its rapid life
cycle and relatively low maintenance costs, Drosophila provides us
with an ideal system to test initial toxicological effects and obtain
dosage information for potential new therapeutic agents. We
evaluated the effects of ORMOSIL throughout the life cycle of the
fly (Figure 2A). Unlike vertebrate model systems, Drosophila is
very amenable to rapid analysis since its life cycle is short [32,33]
and thus effects on an organisms’ entire development can be
quickly analyzed. Briefly, at room temperature (25uC), 1
st instar
larvae hatch within 24 hours after fertilization. Hatched larvae
undergo three larval stages, each stage lasting about a day. After
the 3
rd larval stage, metamorphosis and pupation occur, and after
4–5 days of pupation adult flies eclose. Adult flies typically live for
over 100 days, which also allows studies on aging to be easily
performed.
To test the toxicity of ORMOSIL in a whole organism we fed
RORM (and
cy5ORM, data not shown) to Drosophila larvae that
had just hatched and we continued to feed ORMOSIL through
the developmental cycle of the fly (Figure 2A, red, a total of 39
feeding days and a total of 43 days of exposure). To date no other
animal study has fed nanoparticles or followed their survival for
such a long duration of time and through an organisms’ entire life
cycle.
For our feeding experiments, equal numbers of embryos were
placed in food-containing vials. We used three different forms of
ORMOSIL particles, unconjugated
RORM and two forms of
conjugated-
RORM (TfR-
RORM and peptide-
RORM). We used
Instant Medium (Carolina Biological), which is a commonly used
food for Drosophila in the form of dry flakes to mix all ORMOSIL
formulations (at concentrations of 0.2, 0.4 and 1 mg/ml) for all
feedings. As controls, food was also mixed with the buffer used to
dilute ORMOSIL, (16phosphate buffered saline with 0.1% triton
(1XPBT)) and water. In each food vial containing the different
ORMOSIL formulations (three forms of
RORM each at
concentrations of 0.2, 0.4 and 1 mg/ml), buffer, or water, larvae
were allowed to hatch and were allowed to grow until the larvae
pupated (6 days). During the three larval stages, larvae actively
gorged and only fed on food containing nanoparticles, buffer or
water. During the larval stages, larvae were assayed to determine if
feeding on nanoparticles caused locomotion defects. We failed to
observe any crawling or locomotion defects for larvae fed on the
three forms of ORMOSIL, and these larvae were comparable to
control conditions (buffer and water fed larvae, data not shown,
Table 1). Larval viability changes were also assessed and no
significant difference in the survival of larvae fed on ORMOSIL
was seen compared to buffer or water fed conditions (data not
shown, Table 1). Thus our observations indicate that feeding on
ORMOSIL had no affect on the behavior or on the viability of
larvae (Table 1). Further, unconjugated and conjugated
RORM
fed larvae were undistinguishable from each other.
To test the affect of ORMOSIL on pupal development, we
counted the number of pupae that pupated from ORMOSIL,
buffer and water fed larvae (see methods). Larvae were allowed to
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pupae were counted. No effect was seen in the number of larvae
that pupated between ORMOSIL, buffer or water fed conditions
(Figure 2B, Table 1). Figure 2B depicts the normalized percentage
of pupae for all feeding conditions from three different feeding
experiments. Further, no abnormality was seen in pupation of
ORMOSIL fed larvae compared to buffer or water fed larvae.
Note that since larvae were allowed to pupate in the same food
vials as they fed on, pupae were still exposed to the same food
conditions (4 days of exposure as pupae).
To determine ORMOSIL effects on survival to adulthood, flies
were collected as they eclosed and were placed in new food vials
containing food laced with the corresponding nanoparticle (form
and dose), buffer or water and examined (see methods). We failed
to see any abnormality in flies that survived to adults between
ORMOSIL, buffer or water fed conditions (Figure 2B). No
significant difference in the percentage of flies that eclosed from
pupae for the different feeding conditions were observed
(Figure 2B, Table 1). In addition, there was no abnormality in
the developmental time of when adults emerged from pupae, with
almost all adults emerging on the 3
rd day for all feeding conditions
(Figure 2C). Thus unconjugated or conjugated
RORM appear to
be benign and show good biocompatibility during the entire life
cycle of the fly (10 days).
Figure 1. Physiochemical properties of ORMOSIL nanoparticles. (A) The absorption and emission spectra for rhodamine-ORMOSIL (
RORM)
particles. The typical emission band of rhodamine is lmax 600 nm. (B) The ORMOSIL nanoparticle size distribution profile as measured by the dynamic
light scattering (DLS) method indicates that the diameter of ORMOSIL nanoparticles are on average 20 nm. (C) A transmission electron microscope
(TEM) image of ORMOSIL nanoparticles. Bar=100 nm.
doi:10.1371/journal.pone.0029424.g001
Table 1. Summary of ORMOSIL feeding experiments in Drosophila.
Water Buffer
RORM
0.2
mg/ml
RORM
0.4
mg/ml
RORM
1 mg/ml
Peptide-
R
ORM
0.2 mg/ml
Peptide-
R
ORM
0.4 mg/ml
Peptide-
R
ORM
1 mg/ml
TfR-
RORM
0.2 mg/ml
TfR-
RORM
0.4 mg/ml
TfR-
RORM
1 mg/ml
cy5ORM
1 mg/ml
Larvae
Locomotion
defects
NO NO NO NO NO NO NO NO NO NO NO NO
Viable YES YES YES YES YES YES YES YES YES YES YES YES
Pupae
Viable YES YES YES YES YES YES YES YES YES YES YES YES
Adult flies
Flying defects NO NO NO NO NO NO NO NO NO NO NO NO
Paralysis NO NO NO NO NO NO NO NO NO NO NO NO
Viable YES YES YES YES YES YES YES YES YES YES YES YES
doi:10.1371/journal.pone.0029424.t001
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developmental cycle and ORMOSIL feeding scheme. At room temperature (25uC) larvae hatch from embryos and undergo three larval stages (1
st,2
nd
and 3
rd instar) each lasting approximately 1 day. After the 3
rd instar larval stage larvae begin to pupate. Pupation lasts for 4 days. Once adult flies
eclose they can live for over 100 days. Embryos were collected and placed in food vials containing different forms of ORMOSIL, buffer or water. Larvae
hatch from embryos and immediately begin feeding. All feedings were done until 3
rd instar larvae pupated. The red line depicts the extent of oral
administration of ORMOSIL during Drosophila development. The dashed red line depicts the duration of ORMOSIL exposure. Adult flies that eclosed
from each feeding condition were collected and placed in new food vials containing the same food that they fed on as larvae. The adult flies
continued to feed on different forms of ORMOSIL, buffer or water from the day they eclosed (red arrows). We quantified the survival of adult flies for
33 days (D), while we monitored the survival of adult flies for over 100 days. Note that Drosophila was continuously fed ORMOSIL for a total of 39 to
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adulthood by evaluating adult flies. To test this, the flies that
eclosed from larvae fed on ORMOSIL or control conditions
(buffer and water) were counted and placed in new food vials
containing the corresponding food source (day 0) and the survival
of adult flies were monitored for a total of 33 days. Note that
during these 33 days adult flies were feeding on the same food
source that they fed on as larvae. On day 18, 25, and 33, we
counted the number of flies that had died in each vial and plotted
the percentage of survival on a survival plot (Figure 2D, see
methods). During these 33 days no difference was seen in the
survival of adult flies feeding on ORMOSIL or buffer (Figure 2D,
blue, Table 1). Furthermore, we also failed to see any behavioral
defects. Adult flies were evaluated for flying defects and for the
bang sensitive phenotype, a characteristic phenoytpe that depicts
problems in synapse transmission. Typically flies that show a bang
sensitive phenotype become paralyzed after the flies are given a
mechanical shock such as a bang of the vial on a bench/table
[34,35]. We failed to observe any of these problems in flies fed on
ORMOSIL and their behavior was undistinguishable from buffer
or water fed flies (data not shown, Table 1). We continued to
follow these flies as they aged for over three months (approx 100
days) and found no difference in their survival or in their behavior,
regardless of the feeding regime (data not shown). In our studies
Drosophila was continuously fed ORMOSIL for a total of 39 to
139 days while they were exposed to these particles for a total of 43
to 143 days. Thus continuous feeding of ORMOSIL (unconju-
gated or conjugated) in Drosophila did not affect the behavior or
the survival of adult flies.
The short-term survival of dissected larvae is not affected
by ORMOSIL nanoparticles
To further evaluate the toxicity of ORMOSIL nanoparticles,
we applied ORMOSIL to dissected living larvae and evaluated
their survival. We routinely use this larval dissection procedure in
our laboratory to study the larval nervous system [36] and
dissected larvae can survive under physiological conditions (in
dissection buffer) for at least 180 minutes. Under physiological
conditions larvae were treated with ORMOSIL for 10 minutes
immediately after dissection. The same three doses of
RORM (0.2,
0.4 and 1 mg/ml) that we used for our feeding experiments were
used for larval treatment.
RORM-treated larvae were then washed
with dissection buffer and immediately evaluated. We found that
application of
RORM directly to dissected larvae did not cause any
adverse effects to the dissected living larvae. Similarly application
of
cy5ORM or conjugated
RORM (peptide-
RORM or TfR-
RORM) also did not show any adverse effects (data not shown).
Thus the survival of all ORMOSIL treated larvae (unconjugated
or conjugated) was comparable to buffer treated larvae (Figure 3).
We quantified the survival of dissected living larvae by
evaluating the twitching phenotype. We assigned a ‘‘survival’’
value according to the extent of twitching observed when the larva
was stimulated with a forceps. The twitching phenotype or the
twitch tension is a commonly used phenotype in Drosophila larvae
and evaluates nerve-stimulated contractions of larval body-wall
muscles [37,38,39]. The more the larva twitched or contracted,
the higher the ‘‘survival’’ value, indicating that the dissected larva
is alive. Using this quantification method we found no obvious
difference in the survival of larvae between the three different
doses of ORMOSILor buffer treated larvae (Figure 3). The steady
decline in twitching that we observed for all conditions can be
attributed to a decline in the proper physiological conditions
because the dissection buffer was not replaced every 20–
30 minutes [40]. Taken together our observations indicate that
Figure 3. The short-term survival of dissected living larvae is
not affected by ORMOSIL nanoparticles. Dissected living larvae
were treated with
RORM (1 mg/ml and 0.2 mg/ml are shown) or buffer
and larval survival was quantified by evaluating the twitching
phenotype. We assigned ‘‘survival’’ values or survival points according
to the extent of twitching observed when the larva was stimulated with
a forceps. As described in the text, the more the larva twitched, the
higher the ‘‘survival’’ value, indicating that the dissected larva was alive
[43,44,45]. The extent of twitching was recorded every 15 minutes for a
total of 60 minutes. No significant difference was seen between the
survival of ORMOSIL treated or buffer treated dissected living larvae.
doi:10.1371/journal.pone.0029424.g003
139 days while they were exposed to ORMOSIL for a total of 43 to 143 days. (B) Oral administration of ORMOSIL nanoparticles has no affect on the
survival of Drosophila. The survival of larvae fed on different forms of ORMOSIL was quantified to evaluate survival of pupae and adults. Feedings on
buffer (1XPBT) and water were done as controls. All larvae were allowed to develop into pupae and adults, and the total numbers of pupae and
adults were counted, normalized and graphed as percentage of survival (Y-axis). No significant difference is seen in the survival of pupae (green) and
adults (orange) between the different forms of ORMOSIL, buffer or water fed conditions. (C) Oral administration of ORMOSIL has no affect on the
developmental time of when adult flies eclose from pupae. No significant difference is seen in the total number of adult flies that eclosed from
RORM,
Peptide-
RORM and TfR-
RORM (1 mg/ml) or buffer (1XPBT) fed larvae on 3 different days. On each day the total number of flies were counted,
normalized and graphed as percentage of number of flies eclosing vs day 1, 2 or 3. (D) Oral administration of ORMOSIL nanoparticles has no affect on
the survival of adult flies. The number of adult flies in each food vial was counted on day 0, 18, 25 and 33. The total number of flies in each vial was
normalized to 100 and the survival of adult flies was graphed as a survival curve. Y axis represents the percentage of adults that survived. On day 0
flies were collected, counted and transfered to new food vials. On day 18 flies in each of the vials were again counted. No significant difference in
survival was seen in adult flies fed on
RORM, Peptide-
RORM, TfR-
RORM (1 mg/ml) or buffer. Similarly, on day 25 and 33 flies were again counted and
no significant difference in the rate of survival of adults fed on
RORM, Peptide-
RORM, TfR-
RORM or buffer was seen. Note that these flies fed on
ORMOSIL or buffer for a total of 39 days (6 days as larvae+33 days as adults), while they were exposed to ORMOSIL or buffer for a total of 43 days (6
days as larvae+33 days as adults+4 days exposed as pupape).
doi:10.1371/journal.pone.0029424.g002
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of dissected living larvae.
ORMOSIL nanoparticles incorporate into living larval and
adult neuronal tissues
For a nanoparticle to be successful as a therapeutic tool for
neuronal diseases in humans, it must effectively and specifically
incorporate into living neuronal tissues and must not cause any
adverse effects to living neuronal cells or tissue. To test this, we first
evaluated ORMOSIL incorporation into the Drosophila larval
neuronal tissues. The Drosophila larval nervous system is a
powerful and a well-characterized model system. The central and
peripheral nervous systems are remarkably similar in function and
in morphology to vertebrates. The larval nervous system is highly
organized with the brain at the anterior near the head of the larva
(Figure 4A). Segmental nerves extend from the cell bodies in the
brain along the length of the larva and these nerves end at the
nerve terminals at the distal ends of the larva. Segmental nerves
contain bundles of both motor and sensory neurons and are much
like the sciatic nerve or the brain stem of mammals.
To determine if ORMOSIL can penetrate and integrate into
live larval neuronal tissues, we incubated dissected living larvae
Figure 4. ORMOSIL incorporates into living larval neuronal tissues. (A) A diagram depicting the larval nervous system. The brain is at the
anterior. Segmental nerves that originate at the brain extend along the length of the larvae and form synapses or nerve terminals at their ends.
Segmental nerves contain bundles of motor and sensory axons, with have their cell bodies located in the brain. (B) Buffer treated larval brain. A
representative fluorescence image from a buffer treated larval brain. No fluorescence is observed using the 568 nm filter. Images were taken using
the 106objective. Bar=10 mm. (C) ORMOSIL is observed within the larval nervous system. A representative low magnification (206) light microscopy
image of a larval brain (dashed outline) and segmental nerves show incorporation of
RORM particles (arrows). ORMOSIL is observed within the brain
(outlined, arrows) and the nerves (arrows). Images were obtained using the 568 nm filter to visualize
RORM. Bar=10 mm. (D) ORMOSIL is observed
within the cell bodies of the larval brain. A representative high-magnification fluorescence image using the 1006objective from the ventral ganglion
region of an ORMOSIL treated larval brain shows that
RORM is incorporated into the cytoplasm of the neuronal cell bodies (arrows). Note that the cell
body nuclei are devoid of
RORM and that the fluorescence signal is in a discrete pattern within the cell body (arrows). Bar=5 mm. (E) Unconjugated
ORMOSIL is observed within the larval segmental nerve. A representative high magnification fluorescence image using the 1006objective from a
segmental nerve (outlined) show that
RORM is incorporated into the larval segmental nerve (arrows).
RORM is observed throughout the nerve as
bright puncta (arrows). The fluorescence signal we observe can be attributed to accumulated ORMOSIL. Bar=5 mm (F, G) Conjugated ORMOSIL is
observed within the larval segmental nerve. A representative high magnification fluorescence image using the 1006objective from a segmental
nerve (outlined) show that conjugated ORMOSIL (Peptide-
RORM, F, and TfR-
RORM, G) are incorporated into the larval segmental nerves (arrows).
Bar=5 mm.
doi:10.1371/journal.pone.0029424.g004
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1 mg/ml). Larvae were dissected to expose the larval nervous
system and incubated in ORMOSIL for 10 minutes. Dissected
living larvae were washed in dissection buffer and immediately
observed using a confocal microscope under 568 nm fluorescence
to visualize ORMOSIL integration into larval neuronal tissues.
From our survival experiments we know that ORMOSIL-treated
larvae were alive and can survive to over 60 minutes, so our
observations were conducted within a 30 min time frame.
Unconjugated and conjugated
RORM were found in the larval
brain and in the larval segmental nerves (Figure 4). Similarly we
also found
cy5ORM in the larval brain and larval segmental nerves
(Figure S2). The fluorescence we observe was specific to
ORMOSIL and was not the result of autofluorescence since
buffer or water treated larvae did not show any fluorescence in any
of the larval neuronal tissues (Figure 4B and data not shown). In
addition, while single nanoparticles are below the resolution of the
fluroscence microscope, the fluroscence signal we do observe can
be attributed to the accumulations of ORMOSIL nanoparticles at
single points. High magnification images taken using a 1006
objective indicate that
RORM (or
cy5ORM) was present within the
cytoplasm of the neuronal cell bodies of the larval brain (arrows,
Figure 4D, Figure S2A). Further,
RORM (or
cy5ORM) appears to
be present in specific cellular compartments and the cell body
nuclei appear to be devoid of particles (Figure 4D, Figure S2A).
Indeed, in larval cell bodies, some ORMOSIL puncta (Figure
S3B, red) colocalized with golgi puncta (Figure S3A, green,
merged Figure S3C, arrows). Similar cell body staining was
observed for both conjugated forms of
RORM (data not shown). In
larval segmental nerves,
RORM (or
cy5ORM) was present as
puncta along the length of the segmental nerves (Figure 4E, Figure
S2B arrows). These puncta may represent small aggregates of
ORMOSIL that have accumulated during the 10 min period of
nanoparticle incubation. Similarly, Peptide-
RORM and TfR-
RORM puncta were also observed in larval segmental nerves
(Figure 4F,G arrows). From these observations we can conclude
that ORMOSIL can readily incorporate into living larval
neuronal tissues perhaps into discrete cellular compartments as
suggested previously [26,41].
We also tested ORMOSIL incorporation in living primary
neuronal cultures. Primary neuronal cultures were generated from
wild type larval brains and allowed to grow for 4 days, when
relatively long neuronal projections could be seen. On the fourth
day, cultures were incubated with nanoparticles at the three doses
(0.2, 0.4 and 1 mg/ml) for 10 minutes. Cultures were washed to
remove any unincorporated particles and immediately imaged.
Similar to our observations in larval brains, accumulations of
RORM were seen in the cell body and in the neuritis of primary
neuronal cultures (Figure 5A, arrows). DAPI staining indicates that
the cell body nuclei were also devoid of
RORM particles
(Figure 5FGH). Control cultures treated with buffer did not show
any fluorescence (Figure 5E). To evaluate if
RORM incorporation
caused toxicity to the primary neuronal cultures, and to determine
the retention of ORMOSIL in neurons,
RORM treated cultures
were allowed to grow for 3 more days (for a total of 7 days) and
imaged.
RORM could still be observed 3 days after the initial
nanoparticle treatment, in both the cell bodies (Figure 5B, insert)
and in the neurites (Figure 5B). The fluroscence intensity was
comparable to the initial intensity of
RORM observed 3 days
before (compare Figure 5A to 5B). In addition, these neuronal
cultures were healthy and the neuritis had grown much longer
(about 2 to 3 times longer) during the 3 additional days (Figure 5B).
TfR or peptide-
RORM treatment (Figure 5C, D) also showed a
similar biodistribition and was comparable to unconjugate-
d-
RORM treated primary neuronal cultures. The pattern of
unconjugated, TfR or peptide-
RORM uptake by these neuronal
cells appear to be consistent with previous observations in different
cancer cell lines [8,26,47,41,51]. To further evaluate how
ORMOSIL incorporation affected the growth of neurons in
culture, we compared and quantified growth by quantifying the
changes in the size of the cell body and the changes in the length of
neuronal projections for 120 hours (5 days) after
RORM treatment
(Figure 5IJ). No statistically significant difference in the growth of
either the cell body size or the length of neuronal projections was
observed between non-treated cultures (syntaptotagmin-GFP,
SYNT-GFP expressing cultures) and
RORM treated cultures
(treated with either unconjugated-
RORM (cell body, p=0.728,
neuritis, p=0.698 N=10–12) or peptide-
RORM (cell body,
p=0.737, neuritis, p=0.861, N=8–10) during 120 hours after
RORM treatment. In addition no difference in growth was seen in
cultures treated with either unconjugated-
RORM or peptide-
R-
ORM (cell body, p=0.915, neuritis, p=0.914, N=10). Together,
these observations suggest that ORMOSIL treatment or incorpo-
ration into neurons does not interfere with the normal growth of
neurons. Further, ORMOSIL particles are retained within living
neurons without any aberrant toxicity.
We also evaluated ORMOSIL-fed larvae to determine if these
nanoparticles could incorporate into larval neuronal tissues by
feeding. We failed to see ORMOSIL within the larval brain (data
not shown). However, ORMOSIL was present in many other
larval tissues including the larval gut (Figure S1C), malpighian
tubes (Figure S1C), trachea (Figure S1B) and skin (cutical, Figure
S1B), indicating that these particles can incorporate into larval
tissues by feeding. It is possible that ORMOSIL incorporation into
neuronal tissues require longer exposure times. In this context, we
evaluated adult brains after approx 12–15 days of ORMOSIL
exposure. In these adults ORMOSIL was continuously provided
by feeding; from the time they hatched into larvae until the time
the adults were dissected. Consistent with our hypothesis, we
observe unconjugated and conjugated ORMOSIL in dissected
adult brains (
RORM, Figure 6AB, TfR and peptide-
RORM,
Figure 6CD), while no fluorescence is observed in brains from
control adults (buffer or water fed, compare Figure 6A to 6E).
High magnification (1006) images show that ORMOSIL was
present in clusters or aggregates within the CNS of the adult brain
(Figure 6BCD). These observations were consistent for all 6 adult
brains that were imaged (from 3 different feeding experiments).
We also noted that the ORMOSIL puncta were consistently in the
same region of the brain. These observations suggest that
ORMOSIL can be directed into adult neuronal tissues by feeding.
ORMOSIL nanoparticle incorporation does not activate
aberrant neuronal cell death pathways or interfere with
normal neuronal processes
If these nanoparticles are to be used to develop effective
therapeutic tools for human diseases, these particles by themselves
should not cause any adverse affects to the target tissue. In this
context, we evaluated if ORMOSIL incorporation caused any
adverse effects to the normal cellular processes within neurons,
such as cell viability and axonal transport. To test this, first, larvae
were dissected, treated with ORMOSIL (unconjugated, peptide or
TfR-conjugated), fixed and analyzed using the TUNEL assay to
evaluate if incorporation of ORMOSIL into neuronal cells
activated aberrant neuronal cell death pathways. During cell
death, the DNA within the nucleus becomes fragmented and the
presence of nicked DNA can be identified by terminal deoxynu-
cleotidyl transferase, an enzyme that catalyzes the addition of
dUTPs which can be fluorescently assayed using the TUNEL
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PLoS ONE | www.plosone.org 7 January 2012 | Volume 7 | Issue 1 | e29424Figure 5. ORMOSIL incorporates into cell bodies and neuritis in primary neuronal cultures. (A) Unconjugated ORMOSIL is observed in 4
day old primary neuronal cultures. 4 day old primary neuronal cultures generated from larval brains were incubated with
RORM. Cultures were
imaged using the 568 nm filter.
RORM is observed within the cytoplasm of the cell body in a discrete pattern and within neuritis (arrows). Images
were taken using the 1006objective. Bar=5 mm. (B) Unconjugated ORMOSIL is also observed 3 days after ORMOSIL treatment. To determine how
ORMOSIL affected the growth of cultures, ORMOSIL treated cultures were allowed to grow and again imaged after 3 days of ORMOSIL treatment.
These cultures were now 7 days old. These treated cultures showed growth with very long neuronal projections compared to day 4.
RORM was still
observed within the cell bodies (insert) and the neuritis (arrows,). Note that the fluorescence intensity at day 7 was similar to the intensity observed at
day 4. Images were taken using the 1006objective. Bar=5 mm. (C) Receptor-conjugated ORMOSIL is observed in 4 day old primary neuronal cultures.
4 day old primary neuronal cultures generated from larval brains were incubated with transferrin receptor conjugated ORMOSIL (TfR-
RORM).
TfR-
RORM can be observed within the cell body and within the neuritis. Images were taken using the 1006objective. No significant different in the
distribution of ORMOSIL was seen between
RORM and TfR-
RORM treated cultures. Bar=5 mm. (D) Peptide -conjugated ORMOSIL is observed in 4 day
old primary neuronal cultures. 4 day old primary neuronal cultures generated from larval brains were incubated with peptide-conjugated ORMOSIL
(Peptide-
RORM). Peptide-
RORM can be observed within the cell body and within the neuritis. Images were taken using the 1006 objective. No
significant different in the distribution of ORMOSIL was seen between
RORM and peptide-
RORM treated cultures. Bar=5 mm. (E) Untreated control
cultures. Control 4 day old cultures treated with buffer do not show fluorescence using the 568 nm filter. Images were taken using the 1006
objective. Bar=5 mm. (F, G, H) ORMOSIL is absent from the cell body nucleus. 4 day old primary neuronal cultures were incubated with
RORM (F, red).
Incubated cultures were fixed and stained with DAPI to localize the nuclei (G, blue). A representative merged image (H) indicates that ORMOSIL is
absent from the cell body nucleus. Note that ORMOSIL is present in a discrete pattern within the cell body cytoplasm. Images were taken using the
1006objective. Bar=5 mm. (I) Quantification of cell body growth after ORMOSIL treatment. Graphs depict cell body growth for 120 hours (5 days)
after ORMOSIL treatment. For untreated cultures, cultures expressing synaptotagmin-EGFP (SYNT-EGFP) was used. The effect of treatment was
evaluated for unconjugated ORMOSIL (ORMOSIL) and for peptide-conjugated ORMOSIL (pep-ORMOSIL). For each time point 8–12 cells from three
different experiments were analyzed. The average diameter and standard error was calculated and the average cell body diameter in microns was
plotted against time in hours. No statistically significant difference was seen between ORMOSIL treated (unconjugated or peptide-conjugated) and
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cell death (Figure 7A). We found that ORMOSIL incorporation
into larval cell bodies failed to cause aberrant neuronal death. No
TUNEL-positive nuclei were observed in
RORM treated larval
brains (compare Figure 7B to Figure 7A), although ORMOSIL is
observed within the cell bodies (arrows, Figure 7C). Similar
observations were seen with conjugated
RORM treated larval
brains (data not shown). We further evaluated neuronal cell death
in ORMOSIL fed adult brains. Although ORMOSIL puncta
were observed in adult brains, there were no TUNEL positive
nuclei, indicating that ORMOSIL incorporation by feeding did
not trigger abnormal neuronal cell death in adult ORMOSIL-fed
brains (unconjugated and conjugated
RORM, data not shown).
Thus ORMOSIL incorporation failed to trigger aberrant
neuronal cell death pathways.
Secondly, to determine if ORMOSIL incorporation interfered
with normal cellular processes within the axon we evaluated the
axonal transport pathway using antibodies against the synaptic
vesicle marker, cystein string protein (CSP). Within axons,
essential components are transported from the cell body, the site
where many proteins are synthesized, to the synapse where these
components are utilized. This process known as axonal transport is
essential for the growth, maintenance and survival of all neurons.
Recently, perturbations in this pathway have been implicated in
many human neuronal diseases [42,43]. Previously, we found that
segmental nerves from larvae that contain a mutation for a protein
involved in axonal transport (i.e., a mutation in the gene encoding
the motor protein dynein light chain, DLC) showed bright clusters
of CSP accumulations that we call axonal blockages [30,44]
(Figure 7G, arrows), in contrast to wild type larval segmental
nerves that show smooth CSP staining [30,44]. These blockages
are packed with many types of identifiable axonal cargo, namely
mitochondria, vesicles, large multi-vesicular bodies, and large
prelysosomal vacuoles, which interferes with the normal transport
of components within the axon [45]. Thus we hypothesized that if
ORMOSIL incorporation interfered with the transport of
components within the axon then we should observe axonal
transport defects similar to these blockages. In contrast to larvae
carrying an axonal transport mutation (Figure 7G), ORMOSIL
nanoparticle containing larval segmental nerves were smoothly
stained (compare Figure 7E to 7G), indicating that the presence of
ORMOSIL in larval nerves (Figure 7D arrows) does not cause
aberrant axonal transport defects and does not affect the
distribution of CSP vesicles. Observations were similar in
unconjugated and conjugated forms of
RORM treated larvae
(Figure 7 and data not shown). Thus ORMOSIL incorporation
does not affect the axonal transport pathway.
We further investigated if ORMOSIL incorporation affected
the in vivo transport dynamics of vesicles within larval axons in
whole-mount larvae. Larvae expressing a GFP tagged vesicle
protein (synaptotagmin-EGFP, SYNT-EGFP) were dissected and
treated with ORMOSIL particles (unconjugated or conjugated) at
doses 0.2, 0.4 or 1 mg/ml. Simultaneous observations using dual
view imaging, a beam splitter and split view software showed the
movement of the GFP-tagged synaptotagmin vesicles (Figure 8AC)
within larval axons, together with ORMOSIL (Figure 8BD, data
not shown). The movement dynamics of GFP-tagged synaptotag-
min vesicles was not altered by the incorporation of ORMOSIL
(both unconjugated and conjugated) at these doses, and was
comparable to the movement dynamics of GFP-tagged synapto-
tagmin vesicles in untreated larvae [40]. Similar observations were
also seen in primary neuronal cultures generated from larval
Figure 6. ORMOSIL incorporates into living adult neuronal tissues. (A) Unconjugated ORMOSIL is observed in adult fly brains. A
representative fluorescence image of an adult brain from a fly that was fed on
RORM from the time it was a larvae was dissected and observed using
the 568 nm filter.
RORM aggregates are observed within the adult brain. Images were taken using the 106objective. The boxed region is enlarged in
B. Bar=10 mm. (B) Unconjugated ORMOSIL aggregates are observed as puncta within adult fly brains. A high magnification (using the 1006
objective) image of the boxed region from A.
RORM aggregates (arrows) are seen as puncta within the adult brain. Interestingly, in all 6 adult brains
imaged showed similar puncta of ORMOSIL. Bar=5 mm. (C) Peptide conjugated ORMOSIL aggregates are observed as puncta within adult fly brains. A
representative high magnification image shows peptide-
RORM puncta within the adult brain (arrows). Bar=5 mm. (D) Receptor conjugated ORMOSIL
aggregates are observed as puncta within adult fly brains. A representative high magnification image shows TfR-
RORM puncta within the adult brain
(arrows). Bar=5 mm. (E) No fluorescence is observed in buffer fed adult fly brains. A representative image from a buffer (1XPBT) fed adult fly brain
imaged using the 568 nm filter. Note that there is no fluorescence in these brains. Images were taken using the 106objective. Bar=10 mm.
doi:10.1371/journal.pone.0029424.g006
cultures expressing SYNT-EGFP. (J) Quantification of neurite growth after ORMOSIL treatment. Graphs depict neurite growth for 120 hours (5 days)
after ORMOSIL treatment. For each time point 8–12 cell from three different experiments were analyzed. The average projection length in micron was
plotted against time in hours. The standard error was calculated and plotted. No statistically significant difference was seen in neurite growth
between ORMOSIL treated (unconjugated or peptide-conjugated) and cultures expressing SYNT-EGFP.
doi:10.1371/journal.pone.0029424.g005
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gated and conjugated, data not shown). Thus our observations
indicate that ORMOSIL incorporation at the concentrations we
used does not interfere with the movement of synaptic vesicles in
vivo, an essential pathway for neuronal integrity and survival.
Discussion
For any nanoparticle to be useful as a therapeutic delivery
system, it must first pass three basic criteria; it should not be toxic
to the organism, it should effectively incorporate into the specific
tissue type that the treatment targets and it must not interfere with
the normal functions of that tissue type. Our study demonstrates
that a novel silica based particle named ORMOSIL successfully
passes all three of these tests and could have enormous potential
for the development of a therapeutic system for living neurons
within whole organisms.
Until now, only viral carriers have been successfully used in
treatment strategies in animal models of disease and injury
[47,48], but safety concerns relating to the toxicity and
immunogenicity of viral vectors remain a challenge to clinical
translation [49]. Non-viral delivery vehicles such as ORMOSIL
have the potential to avoid the safety issues inherent in viral
delivery, but lack of knowledge about their behavior in neuronal
tissues and how these particles affect normal cellular processes
within a whole organism has so far limited their use. Our study
tested the behavior of both unconjugated and receptor or peptide
conjugated ORMOSIL in whole living organisms, throughout
development, and in living neuronal cells. We found that these
novel particles are biocompatible, are not cytotoxic and incorpo-
rate into neuronal tissues. Thus these particles have great potential
to be effectively translated for used in neuronal therapeutic
applications.
Unlike other nanoparticles, these nanoparticles have several
physiochemical properties that facilitate their use in many
biomedical applications [8]. They are easily synthesized in a
cost-efficient manner, have excellent storage stability and are
resistant to contamination. They are optically transparent and are
excellent optical probes following encapsulation or conjugation of
flurophores because nano-incorporation protects flurophores from
photobleaching and prevents interaction with the biological
environment [10]. They have also been extensively used as probes
for imaging in in vitro experiments [13]. Further, the porus surface
of ORMOSIL allows co-incorporation of other diagnostic probes
for recognition of molecules for target-specific delivery without
changing its size [11,26].
Previous studies using ORMOSIL nanoparticles in a pancreatic
cancer cell culture system showed no indication of cytotoxicity and
good uptake of these particles was observed using confocal
microscopy [8,19]. Further, fluorescence anisotropy experiments
demonstrated that the flurophores were still coupled to the
particles. Robust uptake was also detected with ORMOSIL
particles conjugated with various biotargeting molecules with no
cytotoxicity. Although studies using systemic injection in mice
have been performed, these studies failed to assess the long-term
toxicity of ORMOSIL to the animal or to the animal’s tissues
[26,18]. Thus we chose Drosophila as a model organism to test
toxicological effects and to obtain dosage information because the
fly has a rapid life cycle and the maintenance costs are relatively
low. Our observations in a whole organism indicate that
ORMOSIL is not toxic to developing Drosophila. Oral admin-
istration of ORMOSIL by feeding to Drosophila, (through its
development) failed to show any developmental defects or induced
lethality. Phenotypically and behaviorally larvae and adults
continuously fed on ORMOSIL were undistinguishable from
those fed on water or buffer. Further more, our feeding
experiments used doses of ORMOSIL that were much higher
than what has previously been used in intravenous experiments in
mice [26,18]. We also failed to see any behavioral defects or any
abnormalities to the adult lifespan in flies that were continuiously
fed ORMOSIL. Importantly, different nanoparticle formulations
with different fluorescent tags and different biotargeting tags
showed very similar behaviors, uptake patterns and distributions
inside living animals and living neuronal cells. Thus these novel
particles appear to be good candidates for the development of
therapeutics in a whole organism. Further, our study is the first to
test the biocompatibility of a nanoparticle through the develop-
ment of an organism and through long-term administration. A
recent invertebrate study in C. elegans examined the effects of a
different kind of nanoparticle in adults, but failed to determine its
effects through the developmental cycle of C. elegans [46].
Recently the biodistribution of ORMOSILwas tested by
systemic injection in mice [26]. In these studies 2.0 mg per kg of
body weight of ORMOSILwas injected into the tail vein and the
incooperation of particles were followed in different tissues. Almost
75% of the injected dose was observed in the liver, spleen and skin,
whereas the lung, kidney and the heart accounted for less than 5%
Figure 7. ORMOSIL incorporation does not activate aberrant
neuronal cell death pathways or affect the axonal transport
pathway. (A, B, C) ORMOSIL nanoparticle incorporation does not
induce aberrant neuronal cell death pathways in the cell bodies of the
larval brain. A control brain incubated with DNAse and treated with the
TUNEL assay shows TUNEL positive cells (A, arrows). A representative
fluorescence image from a larval brain (outlined) incubated with
RORM
was assayed for neuronal cell death using the TUNEL assay. Using the
488 nm filter, no fluorescence was observed in the larval brain
indicating that there were no nuclei showing neuronal cell death (B)
in contrast to A. However,
RORM was present within the larval brain
(using the 568 nm filter, arrows). Note that ORMOSIL is seen as puncta
(C). Images were taken using the 406objective. Bar=20 mm. (D, E, F, G)
ORMOSIL incorporation does not affect the axonal transport pathway. A
representative image of larval segmental nerves from a dissected
RORM
treated larvae does not show axonal blockages using the synaptic
vesicle antibody, CSP (E). Note that ORMOSIL aggregates can be seen in
these larval segmental nerves (arrows, D). F shows the merged image.
In contrast, larval segmental nerves from an axonal transport mutant
(dynein mutant, DLC) show axonal blockages (arrows, G). Images were
taken using the 406objective. Bar=20 mm.
doi:10.1371/journal.pone.0029424.g007
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PLoS ONE | www.plosone.org 10 January 2012 | Volume 7 | Issue 1 | e29424Figure 8. ORMOSIL incorporation does not affect the movement of synaptotagmin vesicles. (A, B) In vivo imaging suggests that ORMOSIL
incorporation does not affect the movement of GFP-tagged synaptotagmin vesicles within living dissected ORMOSIL treated larvae. Single frames
from a representative movie containing both GFP-tagged synaptotagmin vesicles (SYNT-GFP, A) and
RORM (B) simultaneously imaged show the
movement of SYNT-GFP vesicles within a larval segmental nerve incubated with ORMOSIL. Note that the SYNT vesicle shows movement in each
frame (arrow). (B) Note that ORMOSIL is also observed within the same larval segmental nerve (arrow). Note that ORMOSIL does not dramatically
change in each frame (arrow). A 1 min movie is depicted. Movies were taken using the 1006objective. Bar=10 mm. (C,D) Kymographs show that
ORMOSIL treatment does not affect the movement of GFP-tagged synaptotagmin vesicles. Kymographs from the above movies show that the
movement dynamics of SYNT-GFP vesicles are not affected in
RORM treated larvae. The movement of a SYNT-GFP vesicle is seen moving from the left
to the right (arrow, C), while a slight shift is seen for ORMOSIL (arrow, D).
doi:10.1371/journal.pone.0029424.g008
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tissues. Although our feeding experiments also show ORMOSIL
in the gut and skin, in contrast, we found ORMOSIL
incorporation in the adult brain, indicating that continuous
ingestion of ORMOSIL for an extended period of time can lead
to the incorporation of these particles into the adult fly brain.
Although further study is needed to elucidate the exact mechanism
of incorporation, our observations propose that single ORMOSIL
particles may penetrate the Drosophila blood-brain barrier [50]
and form ORMOSIL aggregates. Since penetration of the blood-
brain barrier is an important requirement for an effective
therapeutic particle further study is needed to evaluate the exact
mechanism.
Our observations also indicate that ORMOSIL is an attractive
new particle for the development of therapies specifically targeted
to neuronal tissues. Previous studies have proposed that silica
based nanoparticles can be readily taken up by the cell as
individual entities mostly by phagocytosis or receptor mediated
uptake followed by accumulation in specific cellular compartments
[26,41]. We also found that ORMOSIL particles can readily
incorporate into the cytoplasm of the neuronal cell bodies and to
larval axonal projections or neuritis. The puncta of fluorescence
we observe (Figure 4E, 6B) can be attributed to the fluorescence
from ORMOSIL particles, which entered the cells as individual
entities and accumulated. Incorporation also appears to be to a
specific cellular compartment (Figure S3) and ORMOSIL was
absent from the neuronal cell body nuclei (Figure 5). Importantly,
since both unconjugated and peptide or receptor conjugated
ORMOSIL was seen in cell bodies and neuritis, conjugation of
ORMOSIL does not appear to change the localization of
ORMOSIL within the neuronal cell, although the mechanism of
uptake may be different for unconjugated (by phagacytosis) and
receptor/peptide conjugated (receptor mediated) ORMOSIL
[26,41]. Further study will be needed to elucidate this proposal.
We also observe that the presence of ORMOSIL within
neurons did not activate aberrant neuronal cell death pathways or
interfere with normal neuronal processes such as axonal transport.
Incorporation of ORMOSIL did not induce neuronal cell death.
Further, incorporation of ORMOSIL into living larval axons or
neuritis did not affect the movement dynamics of synaptic vesicles.
Thus while ORMOSIL can affectively incorporate into neurons
these particles do not appear to interfere with normal neuronal
processes, two important requirements for an effective therapeutic
particle.
In conclusion, our study demonstrates that ORMOSIL
nanoparticles have great promise for the development of
therapeutic applications for human neuronal disease for long-
term use within whole organisms. Its non-toxic characteristic and
its ability to readily incorporate into living neuronal tissues
together with its porous surface that allows incorporation of
specific molecules for targeting, make ORMOSIL nanoparticles
the next generation of particles that can be effectively used to
develop targeted therapeutic treatments to specific areas of the
brain or to specific populations of neurons. Development of such
treatment strategies have great potential in minimize global
deleterious affects while maximizing beneficial affects, which is a
problem in many of the current treatment strategies that are used
for many human neuronal diseases.
Materials and Methods
Synthesis of ORMOSIL nanoparticles
ORMOSIL nanoparticles with covalently incorporated fluor-
ophores, rhodamine or cy5, were synthesized in the non-polar core
of an oil-in-water microemulsion, as per our earlier report but with
a slight modification [8]. Briefly, 0.2 g of surfactant AOT and
300 ml of n-butanol and 100 ml of DMSO were dissolved in 10 ml
HPLC grade water by magnetic stirring. To this microemulsion
system, 100 ml of 1 mg/ml of rhodmaine-silane precursor
(rhodamine NHS ester, conjugated to aminopropyltriethoxy
silane) in DMSO was added and stirred, followed by an addition
of 100 ml of neat VTES. The reaction mixture was stirred for
another hour and polymerization reaction was started by the
addition of 10 ml of amino-propyltriethoxysilane. The final
reaction mixture was allowed to stir overnight. The mixture was
then dialyzed against distilled water for 48 h at room temperature,
using a cellulose membrane with a cut-off size of 12–14 kD.
Following dialysis, the nanoparticles were sterile filtered and stored
at 4uC for future use. Using the oil-in-water microemulsion
method
RORM was conjugated with the bioactive molecules
transferrin (Sigma-Aldrich, [8]) and the 15 aa peptide (G-Y-E-N-
P-T-Y-K-F-F-E-Q-M-Q-N, Celtek peptide, [29]). As described
previously [8], 1 mL of stock solution of -COOH-terminated
RORM nanoparticles was mixed with 25 ml of 0.1 M EDC
solution and gently stirred for 30 min. Next, 5 ml of 5 mg/mL of
transferrin or 5 ml of 5 mg/ml of peptide was added into this
mixture, and the mixture was incubated at room temperature for
2 h to allow the proteins to covalently bond to the COOH group
of the ORMOSIL nanoparticles. The conjugation was confirmed
by agarose gel electrophoresis by measuring the f-potential values
of the resulting nanoparticles [8].
Drosophila feeding experiments
Wild type Drosophila cages were used to collect embryos for
ORMOSIL (unconjugated or receptor or peptide conjugated)
feeding experiments. Eggs were collected on egg laying apple
plates for 12 hours at room temperature. Using a brush the eggs
were collected into a fine sieve, washed and placed in a
microcentrifuge tube in a suspension of water. 200 ml of egg/
water solution was placed in each vial that contained dry food
(Instant Medium, Carolina Biological, which is a commonly used
food for Drosophila), mixed with the three different doses of
ORMOSIL (0.2, 0.4 and 1 mg/ml), 1X PBT (Phosphate Buffered
Saline (PBS) containing triton X-100) buffer or water. 1 mg/ml
ORMOSIL were diluted to 0.2 and 0.4 mg/ml using 1X PBT
buffer. Similar procedures were previously used in a chemical
screen that tested 500 small molecular compounds to identify
chemical modifiers of axonal blockages (Gunawardena unpub-
lished). In this screen we found that feedings using concentrations
of 1 mg/ml of modifier compound was very toxic to developing
Drosophila (Gunawardena unpublished). Thus we determined that
concentrations of 1 mg/ml and below were ideal for nanoparticle
feeding experiments in Drosophila.
Vials containing food laced with the different forms of
ORMOSIL, buffer or water were kept in the dark in a humid
chamber and the larval, pupae and adult development was
observed at room temperature (25uC). At each developmental
stage of the Drosophila life cycle, larvae, pupae and adults were
counted. The larvae were counted as the larvae crawled up the
vial. The pupae were counted as the larvae pupated. As adults
eclosed from pupae they were counted and placed in a new vial
that contained the corresponding concentration of ORMOSIL,
buffer or water. The survival of adults was assayed for over 100
days.
To assay for ORMOSIL incorporation, ORMOSIL fed whole
3
rd instar larvae were mounted on a slide and imaged under a
Nikon TE 2000 fluorescent microscope. For visualization of
RORM/
cy5ORM the 568/680 nm filter was used to observe
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buffer fed and water fed larvae were also imaged. These larvae did
now show any fluorescence in the 568 nm/680 nm filter (Figure
S1DE and data not shown). For each condition over 10 larvae
were imaged. Visualization was also done using the 488 nm filter.
Images were also taken in phase contrast to visualize the whole
larvae (Figure S1A).
Quantification of survival of larvae, pupae and adults
To quantify the survival of ORMOSIL and control fed larvae
we counted and labeled larvae using a colored pen. Each day new
larvae were counted and recorded were recorded for each
experimental condition. As the larvae pupated each pupae was
counted and labeled using a different colored pen to determine the
survival of pupae. Each day new pupae were counted and the total
numbers of pupae were recorded for each condition. Further, as
adults emerged they were collected, counted and placed in new
vials containing food laced with the appropriate feeding condition.
This day was recorded as Day 0. More than 100 flies from 3
experiments were pooled for quantification and graphing. For
each feeding condition the total numbers of pupae and adults were
normalized and graphed as percent survival (Figure 2B). Once
adults started eclosing the numbers of adult flies eclosing on 3
constisutive days were counted and normalized to determine if
there was a delay in development between the different feeding
conditions (Figure 2C). To generate the survival curve the number
of dead adults were counted on day 18, 25 and 33. These numbers
were subtracted from the total number of flies on day 0 and
normalized and plotted as percent survival (Figure 2D). Note that
survival of adult flies was counted for a total of 33 days, although
vials were evaluated for over 100 days. Student T-test was used to
determine statistically significant differences between the feeding
conditions. Graphs were plotted using an EXCEL spreadsheet.
Larval dissections and adult brain dissections
Larvae were dissected as described previously in 16 dissection
buffer, under physiological conditions [30,36]. Usually during
dissections, the buffer is replaced every 20–30 minutes to keep the
physiological conditions constant and under these conditions
dissected larvae survive for over 180 minutes. However, since we
were evaluating the effect of ORMOSIL on dissected larval survival,
the buffer was not changed. Under these modified conditions the
dissected larvae survived for more than 60 minutes. ORMOSIL or
dissection buffer was added to living dissected larvae and incubated
for 10 minutes at room temperature in the dark. After treatment the
living dissected larvae were washed with dissection buffer and
mounted for immediate observation using a Nikon TE 2000
fluorescent microscope using the 568 nm filter or a Leica TCS
SP2 AOBS spectral confocal microscope (Leica Microsystems
Semiconductor GmbH, Wetzler, Germany) using the krypton/
argon laser. Images were obtained using a 1006or 636objective.
The survival of dissected living larvae incubated with ORMO-
SIL or dissection buffer was quantified using ‘‘survival points’’.
‘‘Survival points’’ were assigned according to the extent of
twitching observed when the larva was stimulated with a forceps
[37,38,39]. The higher the survival value the more the larva
twitched, indicating that the larva was alive. The lower the survival
value the less the larva twitched and was more likely to be dying.
The twitching phenotype or the twitch tension is a commonly used
phenotype in Drosophila larvae and evaluates nerve-stimulated
contractions of larval body-wall muscles [37,38,39]. For each
condition the survival of 10 treated larvae was followed for
60 minutes. The extent of twitching for each larva was recorded
every 15 minutes for a total of 60 minutes. Graphs were plotted
using an EXCEL worksheet, with the Y axis depicting the larval
survival and the x axis depicting the time in minutes (Figure 3).
Adult flies fed on ORMOSIL or control conditions were aged for
10 days and their brains were dissected using 16dissection buffer. 6
dissected brains for each feeding condition were immediately
mounted and imaged using the 568 nm filter to image for
ORMOSIL incorporation using a 206and 406objective.
Immunohistochemistry, TUNEL assay and Confocal
Imaging
Dissected larvae were treated with ORMOSIL, buffer or water
as described above and fixed in 4% formaldehyde. Immunohis-
tochemistry was performed as previously described in [30,44,36].
Briefly, fixed larvae were washed in 1XPBT and incubated
overnight with antibodies against CSP (cysteine string protein, a
synaptic vesicle protein, Developmental Studies Hybridoma
Bank), to assay for axonal blockages at a dilution of 1:10. The
primary antibody were incubated overnight at 4uC. The
secondary antibody Alexa 488 anti-mouse (Invitrogen) was used
at a concentration of 1:200 since ORMOSILwas imaged using the
568 nm filter. The secondary antibody was incubated for one hour
at room temperature in the dark. After washing with 1XPBT,
larvae were mounted on slides using vectorshield mounting
medium for confocal microscopy using a Leica TCS SP2 AOBS
spectral confocal microscope (Leica Microsystems Semiconductor
GmbH, Wetzler, Germany). Images were taken using a 636 oil
immersion objective using the krypton/argon laser to image the
synaptic protein CSP in 488 nm and ORMOSIL in 568 nm.
To evaluate cell death, the TUNEL assay (Roche) was performed
as previously described in [30,44]. Larval brains were dissected in
16dissection buffer and incubated in ORMOSIL similar to what
was done in larval dissections. Larval brains were fixed using 4%
formaldehyde and the TUNEL assay was performed as per
manufactures instructions. Negative (no substrate) and positive
(DNAse digestion of larval brains, Figure 7A) were done as controls
to test the sensitivity of the assay. Larval brains were mounted using
vectorshield mounting medium and imaged using the confocal
microscope using the krypton/argon laser to assay for cell death in
488 nm and ORMOSIL incorporation in 568 nm. Images were
taken usingthe636oilimmersionobjectiveand the LeicaTCS SP2
AOBS spectral confocal microscope.
In vivo imaging of GFP-tagged vesicles and ORMOSIL in
dissected living larval segmental nerves
GFP-expressing larvae were generated by crossing males that
carried the transgene synaptotagmine-EGFP (UAS-SYNT-EGFP)
to female virgins that carried the transgene APPL-GAL4 as
described in [44,40]. In the progeny the activator GAL4 binds to
the GAL4 binding sites of UAS-SYNT-EGFP thus expressing the
synaptotagmin-EGFP vesicle protein. GAL4 expression is con-
trolled by a neuronal specific promoter (APPL) thus SYNT-EGFP
expression only occurs in neuronal tissues. Synaptotagmin is a
vesicle protein. GFP expressing larvae are dissected and incubated
with ORMOSIL as described above. After ORMOSIL incubation
(10 minutes), ORMOSIL was washed using dissection buffer.
These dissected larvae are immediately imaged using the 1006oil
immersion objective. Using the beam splitter and split view
software simultaneous movies are obtained for GFP (488 nm filter)
and
RORM (568 nm filter), using the Nikon TE 2000 fluorescent
microscope. Simultaneous movies of GFP vesicles and ORMOSIL
particles containing 100 frames were taken at 150 msec as
previously done [44,40]. Kymographs of each movie are generated
using MetaMorph software.
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quantification of neuronal growth
Primary neuronal cultures were generated from wild type 3
rd
instar larval brains as previously described [51]. Briefly, larval
brains are dissected, washed with ethanol and incubated in a
Liberase enzyme solution (17 ul liberase solution and 1 mL of
Ranaldini’s Saline) for 1 hour at 29 degrees. The enzyme is
replace by medium and the medium is replace three times. After
the last replacement with medium, the neurons are resuspended
with a pipette to break the cells. The suspension of cells is pipetted
onto culture dishes containing glass coverslip bottoms and
incubated at 29 degrees. Cultures are flooded with flooding
medium (S10-I medium and 20E hormone). The cultures are
allowed to grow for 4 days at 29 degrees. On the 4
th day, the
flooding medium is replaced with the flooding medium containing
different forms of ORMOSIL (0.2 mg/ml, 0.4 mg/ml and 1 mg/
ml) or buffer for 10 minutes at 29 degrees. After 10 minutes the
cultures are washed with flooding medium and immediately
imaged using the Nikon TE 2000 fluorescent microscope, the
1006oil immersion objective and the 568 nm filter. After imaging
the cultures are allowed to grow for another 3 days at 29 degrees.
These cultures (7 days old) are again imaged to evaluate the
growth of these cultures 3 days after ORMOSIL incorporation.
The growth in ORMOSIL treated cultures is evaluated by
comparing the lengths of neuritis in ORMOSIL treated cultures to
non-treated cultures. Both ORMOSIL treated and non-treated
cultures showed 2–3 times longer neuritis at 7 days than 4 days. 4
day old cultures were also treated with Transferrin and peptide-
conjugated ORMOSIL as described above.
To quantifying neuronal cell growth in cultures the diameter of
the cell body and neurite length were measured. For neurite length
the longest projection was used. Quantification was done in
untreated cultures expressing SYNT-EGFP and in cultures treated
with unconjugated and peptide conjugated ORMOSIL. All
measurements were taken in MetaMorph using the multi-line
tracing tool. To measure the cell body diameter, a linear line was
traced through the cell body end to end. In the case of
asymmetrical cell bodies, two lines were used perpendicular to
each other and averaged to get the diameter. To measure the
neurite length, one line was traced along the length of the longest
neurite. Any cells lacking visible neurites were omitted from the
analysis. Measurements were obtained from 8 to 12 individual
cells and averaged. Data was plotted on an Excel worksheet and
the standard error and p values were calculated.
Supporting Information
Figure S1 ORMOSIL conjugated with Cy5 also pene-
trates into larval cell bodies and larval segmental
nerves. (A)
Cy5ORM treated larvae show ORMOSIL in larval
cell bodies (arrows), similar to figure 4D. Note that the cell body
nuclei are devoid of ORMOSIL. Bar=5 mm. (B) A representative
high magnification fluorescence image from a segmental nerve
(outlined) shows that
cy5ORM is also incorporated into the larval
segmental nerve (arrows).
cy5ORM is observed throughout the
nerve as bright puncta (arrows). The fluorescence signal we observe
can be attributed to accumulated ORMOSIL. Bar=5 mm.
(TIF)
Figure S2 ORMOSIL nanoparticles incorporate into
living larval tissues. (A) A composite phase contrast image of
a living larva. The head is at the anterior end while the tail is at the
posterior end. These images of whole larvae were constructed by
putting together several images taken using the 106objective. (B) A
composite fluorescence image of an ORMOSIL fed living larva
imaged for
RORM using the 568 nm filter. ORMOSIL nanopar-
ticles can be observed within the skin (cuticle) and trachea (anterior
posterior lines). Bar=100 mm. (C) A composite fluorescence image
of an ORMOSIL fed living larva imaged for
RORM. Note that
ORMOSIL nanoparticles areobserved aspunctaand arepresentin
the guts and malpighian tubes. (D) A composite fluorescence image
of a control, buffer (1XPBT) fed living larva imaged using the
568 nm filter. Note that no distinct fluorescence is observed. (E) A
composite fluorescence image of a control, water fed living larva
imaged using the 568 nm filter. No obvious fluorescence is
observed. The guts show some auto fluorescence, but note that
the staining pattern is different from what is seen in C and B.
(TIF)
Figure S3 ORMOSIL is present within specific cellular
compartments. (A) A representative image showing cell bodies
from ORMOSIL treated larval brains stained with the golgi
marker gp120 (green). (B) ORMOSIL can be observed in red.
Note that some ORMOSIL puncta and golgi puncta colocalize
(arrows in merged image, C) indicating that ORMOSIL is present
within discret compartments within the cell body and is not at the
cell surface. Bar=5 mm.
(TIF)
Acknowledgments
We thank Hasan Hasanov for troubleshooting initial larval lethality
experiments, Dr Restifo for assistance with the primary neuronal culture
protocol, Drs Slaughter and Hollingsworth for helpful comments, Kate
Kowalski for editorial assistance and Dr Karunaratne for constant support.
We also thank to our anonymous reviewers for their comments and
suggestions. We dedicate this work to the memory of Herschel
Gunawardena and Tom Gehrels.
Author Contributions
Conceived and designed the experiments: FB PLN RK GJI MLK AK EJB
PNP SG. Performed the experiments: FB PLN RK GJI MLK AK.
Analyzed the data: FB PLN GJI AK SG. Wrote the paper: RK EJB SG.
References
1. Kim S, Lim YT, Soltesz EG, De Grand AM, Lee J, et al. (2004) Near-infrared
fluorescent type II quantum dots for sentinel lymph node mapping. Nat
Biotechnol 22: 93.
2. Nyk M, Kumar R, Ohulchanskyy TY, Bergey EJ, Prasad PN (2008) High
contrast in vitro and in vivo photoluminescence bioimaging using near infrared to
near infrared up-conversion in Tm3+ and Yb3+ doped fluoride nanophosphors.
Nano Lett 8: 3834.
3. Deissler V, Ruger R, Frank W, Fahr A, Kaiser WA, et al. (2008) Fluorescent
liposomes as contrast agents for in vivo optical imaging of edemas in mice. Small
4: 1240.
4. Ghoroghchian PP, Frail PR, Susumu K, Blessington D, Brannan AK, et al.
(2005) Near-infrared-emissive polymersomes: self-assembled soft matter for in
vivo optical imaging. Proc Natl Acad Sci USA 102: 2922.
5. Altinoglu EI, Russin TJ, Kaiser JM, Barth BM, Eklund PC, et al. (2008) Near-
infrared emitting fluorophore-doped calcium phosphate nanoparticles for in vivo
imaging of human breast cancer. ACS Nano 2: 2075.
6. Josephson L, Kircher MF, Mahmood U, Tang Y, Weissleder R (2002) Near-
infrared fluorescent nanoparticles as combined MR/optical imaging probes.
Bioconjugate Chem 13: 554.
7. Park JH, von Maltzahn G, Ruoslahti E, Bhatia SN, Sailor MJ (2008) Micellar
hybrid nanoparticles for simultaneous magnetofluorescent imaging and drug
delivery. Angew Chem Int Ed 47: 7284.
8. Kumar R, Roy I, Ohulchanskyy TY, Goswami LN, Bonoiu AC, et al. (2008)
Covalently dye-linked, surface-controlled, and bioconjugated organically
modified silica nanoparticles as targeted probes for optical imaging. ACS Nano
2: 449.
Nanoparticles in Drosophila
PLoS ONE | www.plosone.org 14 January 2012 | Volume 7 | Issue 1 | e294249. Slowing II, Wu CW, Vivero-Escoto JL, Lin VS (2009) Mesoporous silica
nanoparticles for reducing hemolytic activity towards mammalian red blood
cells. Small 5: 57–62.
10. Ow H, Larson DR, Srivastava M, Baird BA, Webb WW, et al. (2005) Bright and
stable core-shell fluorescent silica nanoparticles. Nano Lett 5: 113.
11. Zhao X, Hilliard LR, Mechery SJ, Wang Y, Bagwe RP, et al. (2004) A rapid
bioassay for single bacterial cell quantitation using bioconjugated nanoparticles.
Proc Natl Acad Sci USA 101: 15027.
12. Sharma RK, Das S, Maitra A (2004) Surface modified ormosil nanoparticles.
J Colloid Interface Sci 277: 342–6.
13. Qian J, Li X, Wei M, Gao X, Xu Z, et al. (2008) Bio-molecule-conjugated
fluorescent organically modified silica nanoparticles as optical probes for cancer
cell imaging. Opt Express 16: 19568–78.
14. Walcarius A, Ganesan V (2006) Ion-exchange properties and electrochemical
characterization of quaternary ammonium-functionalized silica microspheres
obtained by the surfactant template route. Langmuir 22: 469–77.
15. Han L, Sakamoto Y, Che S, Terasaki O (2009) Insight into the defects of cage-
type silica mesoporous crystals with Fd3m symmetry: TEM observations and a
new proposal of ‘‘polyhedron packing’’ for the crystals. Chemistry 15: 2818–25.
16. Santra S, Liesenfeld B, Dutta D, Chatel D, Batich CD, et al. (2005) Folate
conjugated fluorescent silica nanoparticles for labeling neoplastic cells. J Nanosci
Nanotechnol 5: 899–904.
17. Santra S, Yang H, Dutta D, Stanley JT, Holloway PH, et al. (2004) TAT
conjugated, FITC doped silica nanoparticles for bioimaging applications. Chem
Commun (Camb) 24: 2810–1.
18. Bharali DJ, Klejbor I, Stachowiak EK, Dutta P, Roy I, et al. (2005) Organically
modified silica nanoparticles: a nonviral vector for in vivo gene delivery and
expression in the brain. Proc Natl Acad Sci U S A 102: 11539–44.
19. Roy I, Ohulchanskyy TY, Pudavar HE, Bergey EJ, Oseroff AR, et al. (2003)
Ceramic-based nanoparticles entrapping water-insoluble photosensitizing anti-
cancer drugs: a novel drug-carrier system for photodynamic therapy. J Am
Chem Soc 125: 7860–5.
20. Kim S, Ohulchanskyy TY, Pudavar HE, Pandey RK, Prasad PN (2007)
Organically modified silica nanoparticles co-encapsulating photosensitizing drug
and aggregation-enhanced two-photon absorbing fluorescent dye aggregates for
two-photon photodynamic therapy. J Am Chem Soc 129: 2669–75.
21. Adams MD, Celniker SE, Holt RA, Evans CA, Gocayne JD, et al. (2000) The
genome sequence of Drosophila melanogaster. Science 287: 2185–95.
22. Lessing D, Bonini NM (2009) Maintaining the brain: insight into human
neurodegeneration from Drosophila melanogaster mutants. Nat Rev Genet 10:
359–70.
23. Affleck JG, Walker VK (2008) A role for Drosophila in understanding drug-
induced cytotoxicity and teratogenesis. Cytotechnology 57: 1–9.
24. Nichols CD (2006) Drosophila melanogaster neurobiology, neuropharmacology,
and how the fly can inform central nervous system drug discovery. Pharmacol
Ther 112: 677–700.
25. Rand MD (2010) Drosophotoxicology: the growing potential for Drosophila in
neurotoxicology. Neurotoxicol Teratol 32: 74–83.
26. Kumar R, Roy I, Ohulchanskky TY, Vathy LA, Bergey EJ, et al. (2010) In vivo
biodistribution and clearance studies using multimodal organically modified
silica nanoparticles. ACS Nano 4: 699–708.
27. Qu L, Akbergenova Y, Hu Y, Schikorski T (2009) Evolutionary conservation of
vertebrate blood-brain barrier chemoprotective mechanisms in Drosophila.
J Comparative Neurology 514: 343–352.
28. de Jong G, van Dijk JP, van Eijk HG (1990) The biology of transferrin. Clin
Chim Acta 190: 1–46.
29. Qian ZM, Li AN, Sun H, Ho K (2002) Targeted Drug Delivery via the
Transferrin Receptor- Mediated Endocytosis Pathway. Pharmacol Rev 54:
561–587.
30. Gunawardena S, Goldstein LS (2001) Disruption of axonal transport and
neuronal viability by amyloid precursor protein mutations in Drosophila.
Neuron 32: 389–401.
31. Satpute-Krishnan P, Degiorgis JA, Conley MP, Jang M, Bearer EL (2006) A
peptide zipcode sufficient for anterograde transport within amyloid precursor
protein. Proc Natl Acad Sci U S A 103: 16532–7.
32. Ashburner M, Thompson JN (1978) The laboratory culture of Drosophila.I n :
Ashburner M, Wright TRF, eds. The Genetics and Biology of Drosophila, vol. 2a.
London: Academic Press. pp 1–109.
33. Ashburner M, Golic KG, Hawley RS (2005) Drosophila: a laboratory handbook.
Second edition. pp xxviii + 1408.
34. Pavlidis P, Tanouye MA (1995) Seizures and failures in the giant fiber pathway
of Drosophila bang-sensitive paralytic mutants. J Neurosci 8: 5810–9.
35. Lee J, Wu CF (2002) Electroconvulsive seizure behavior in Drosophila: analysis
of the physiological repertoire underlying a stereotyped action pattern in bang-
sensitive mutants. J Neurosci 22: 11065–79.
36. Fye S, Dolma K, Kang MJ, Gunawardena S (2010) Visualization of larval
segmental nerves in 3
rd instar Drosophila larval preparations. J Vis Exp 43:
2128.
37. Hewes RS, Snowdeal EC, 3rd, Saitoe M, Taghert PH (1998) Functional
redundancy of FMRFamide-related peptides at the Drosophila larval neuro-
muscular junction. J Neurosci 18: 7138–51.
38. Meeusen T, Mertens I, Clynen E, Baggerman G, Nichols R, et al. (2002)
Identification in Drosophila melanogaster of the invertebrate G protein-coupled
FMRFamide receptor. Proc Natl Acad Sci U S A 99: 15363–8.
39. Pereanu W, Spindler S, Im E, Buu N, Hartenstein V (2007) The emergence of
patterned movement during late embryogenesis of Drosophila. Dev Neurobiol
67: 1669–85.
40. Kuznicki ML, Gunawardena S (2010) In vivo visualization of synaptic vesicles
within Drosophila larval segmental axons. J Vis Exp 44: 2151.
41. Ohulchanskyy TY, Roy I, Goswami LN, Chen Y, Bergey EJ, et al. (2007)
Organically modified silica nanoparticles with covalently incorporated photo-
sensitizer for photodynamic therapy of cancer. Nano Lett 7: 2835–42.
42. Gunawardena S, Goldstein LS (2005) Polyglutamine diseases and transport
problems: deadly traffic jams on neuronal highways. Arch Neurol 62: 46–51.
43. Gunawardena S, Goldstein LS (2004) Cargo-carrying motor vehicles on the
neuronal highway: transport pathways and neurodegenerative disease.
J Neurobiol 58: 258–71.
44. Gunawardena S, Her LS, Brusch RG, Laymon RA, Niesman IR, et al. (2003)
Disruption of axonal transport by loss of huntingtin or expression of pathogenic
polyQ proteins in Drosophila. Neuron 40: 25–40.
45. Hurd DD, Saxton WM (1996) Kinesin mutations cause motor neuron disease
phenotypes by disrupting fast axonal transport in Drosophila. Genetics 144:
1075–85.
46. Pluskota A, Horzowski E, Bossinger O, von Mikecz A (2009) In Caenorhabditis
elegans nanoparticle-bio-interactions become transparent: silica-nanoparticles
induce reproductive senescence. PLoS One 4: e6622.
47. Kaspar BK, Llado ´ J, Sherkat N, Rothstein JD, Gage FH (2003) Retrograde viral
delivery of IGF-1 prolongs survival in a mouse ALS model. Science 301: 839–42.
48. Kells AP, Fong DM, Dragunow M, During MJ, Young D, et al. (2004) AAV-
mediated gene delivery of BDNF or GDNF is neuroprotective in a model of
Huntington disease. Mol Ther 9: 682–8.
49. Hsich G, Sena-Esteves M, Breakefield XO (2002) Critical issues in gene therapy
for neurologic disease. Hum Gene Ther 13: 579–604.
50. Mayer F, Mayer N, Chinn L, Pinsonneault RL, Kroetz D, et al. (2009)
Evolutionary conservation of vertebrate blood-brain barrier chemoprotective
mechanisms in Drosophila. J Neurosci 29: 3538–50.
51. Kraft R, Levine RB, Restifo LL (1998) The steroid hormone 20-hydroxyecdy-
sone enhances neurite growth of Drosophila mushroom body neurons isolated
during metamorphosis. J Neurosci 18: 8886–99.
Nanoparticles in Drosophila
PLoS ONE | www.plosone.org 15 January 2012 | Volume 7 | Issue 1 | e29424